NO20041203L - Human glukagonlignende peptid-1 etterligner og deres anvendelse i behandling av diabetes og relaterte tilstander. - Google Patents

Human glukagonlignende peptid-1 etterligner og deres anvendelse i behandling av diabetes og relaterte tilstander.

Info

Publication number: NO20041203L
Authority: NO; Norway
Prior art keywords: mimics; diabetes; peptide; treatment; related conditions
Prior art date: 2001-10-18

Application number

NO20041203A

Other languages

English (en)

Inventor

Sesha Natarajan

Margarita M Bastos

Michael S Bernatowicz

Claudio Mapelli

Lee Ving

William R Ewing

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-18

Filing date

2004-03-23

Publication date

2004-06-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23339970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20041203(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-03-23 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2004-06-10 Publication of NO20041203L publication Critical patent/NO20041203L/no

Links

DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
101500028774 Homo sapiens Glucagon-like peptide 1 Proteins 0.000 title 1
206010012601 diabetes mellitus Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Zoology (AREA)
Cardiology (AREA)
Toxicology (AREA)
Ophthalmology & Optometry (AREA)
Child & Adolescent Psychology (AREA)
Biomedical Technology (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Neurology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20041203A 2001-10-18 2004-03-23 Human glukagonlignende peptid-1 etterligner og deres anvendelse i behandling av diabetes og relaterte tilstander. NO20041203L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US34201501P	2001-10-18	2001-10-18
PCT/US2002/033386 WO2003033671A2 (en)	2001-10-18	2002-10-18	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions

Publications (1)

Publication Number	Publication Date
NO20041203L true NO20041203L (no)	2004-06-10

Family

ID=23339970

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20041203A NO20041203L (no)	2001-10-18	2004-03-23	Human glukagonlignende peptid-1 etterligner og deres anvendelse i behandling av diabetes og relaterte tilstander.

Country Status (21)

Country	Link
US (3)	US7238670B2 (no)
EP (1)	EP1572892A4 (no)
JP (1)	JP2005514337A (no)
KR (1)	KR20040054729A (no)
CN (1)	CN1630709A (no)
AU (1)	AU2002348469B2 (no)
BR (1)	BR0213377A (no)
CA (1)	CA2463908A1 (no)
GE (1)	GEP20063908B (no)
HR (1)	HRP20040343A2 (no)
HU (1)	HUP0700151A2 (no)
IL (1)	IL160917A0 (no)
IS (1)	IS7185A (no)
MX (1)	MXPA04003553A (no)
NO (1)	NO20041203L (no)
NZ (1)	NZ531788A (no)
PL (1)	PL377687A1 (no)
RU (1)	RU2353625C2 (no)
WO (1)	WO2003033671A2 (no)
YU (1)	YU31004A (no)
ZA (1)	ZA200402846B (no)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2463908A1 (en) *	2001-10-18	2003-04-24	Bristol-Myers Squibb Company	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7238671B2 (en)	2001-10-18	2007-07-03	Bristol-Myers Squibb Company	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
AU2003264256A1 (en) *	2002-09-04	2004-03-29	Dsm Ip Assets B.V.	A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
EP1617888B1 (en)	2003-04-23	2019-06-12	Valeritas, Inc.	Hydraulically actuated pump for long duration medicament administration
WO2004103993A1 (en)	2003-05-14	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
TR201906789T4 (tr)	2003-11-20	2019-05-21	Novo Nordisk As	Üretim ve enjeksiyon cihazlarında kullanım için en uygun olan propilen glikol ihtiva eden peptit formülasyonları.
US7521527B2 (en) *	2003-12-16	2009-04-21	Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S.	GLP-1 pharmaceutical compositions
ES2282062T1 (es)	2004-06-04	2007-10-16	Teva Pharmaceutical Industries Ltd.	Composicion farmaceutica que contiene irbesartan.
US7145040B2 (en) *	2004-07-02	2006-12-05	Bristol-Myers Squibb Co.	Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
TW200611704A (en) *	2004-07-02	2006-04-16	Bristol Myers Squibb Co	Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
WO2006014425A1 (en) *	2004-07-02	2006-02-09	Biovalve Technologies, Inc.	Methods and devices for delivering glp-1 and uses thereof
US7534763B2 (en)	2004-07-02	2009-05-19	Bristol-Myers Squibb Company	Sustained release GLP-1 receptor modulators
AR051446A1 (es)	2004-09-23	2007-01-17	Bristol Myers Squibb Co	Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US7635699B2 (en)	2004-12-29	2009-12-22	Bristol-Myers Squibb Company	Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7589088B2 (en)	2004-12-29	2009-09-15	Bristol-Myers Squibb Company	Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
DOP2006000008A (es) *	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US7521557B2 (en)	2005-05-20	2009-04-21	Bristol-Myers Squibb Company	Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
WO2006127948A2 (en) *	2005-05-26	2006-11-30	Bristol-Myers Squibb Company	N-terminally modified glp-1 receptor modulators
BRPI0615573A2 (pt) *	2005-09-08	2011-05-24	Tufts College	análogos de glp-1 estabilizados
GEP20135838B (en)	2005-09-14	2013-06-10	Takeda Pharmaceutical	Dipeptidyl peptidase inhibitors usage at diabetes treatment
CN101360723A (zh)	2005-09-16	2009-02-04	武田药品工业株式会社	制备嘧啶二酮衍生物的方法
EP1943215A2 (en)	2005-10-31	2008-07-16	Brystol-Myers Squibb Company	Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
EP1943275B1 (en) *	2005-11-01	2010-06-16	Activotec SPP Limited	Insulinotropic compounds and uses thereof
EP2570133B1 (en)	2005-11-07	2016-03-23	Indiana University Research and Technology Corporation	Glucagon analogs exhibiting physiological solubility and stability
GB0526291D0 (en)	2005-12-23	2006-02-01	Prosidion Ltd	Therapeutic method
EP1976873A2 (en) *	2006-01-11	2008-10-08	Brystol-Myers Squibb Company	Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
CN101389648B (zh) *	2006-02-22	2013-07-17	默沙东公司	肽胃泌酸调节素衍生物
PE20080168A1 (es) *	2006-03-23	2008-02-25	Bristol Myers Squibb Co	Preparacion enzimatica de (s)-aminoacido a partir del (r,s)-aminoacido o a partir del ceto acido
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
CN103239773B (zh)	2006-03-30	2015-08-26	瓦莱里塔斯公司	多筒式流体递送器械
PE20071221A1 (es)	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
SG10201404220TA (en)	2006-04-11	2014-10-30	Arena Pharm Inc	Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
CA2649751A1 (en) *	2006-04-20	2007-11-01	Amgen Inc.	Glp-1 compound/glucagon antibody compositions
US20100022457A1 (en) *	2006-05-26	2010-01-28	Bristol-Myers Squibb Company	Sustained release glp-1 receptor modulators
US7919598B2 (en)	2006-06-28	2011-04-05	Bristol-Myers Squibb Company	Crystal structures of SGLT2 inhibitors and processes for preparing same
US20080044326A1 (en) *	2006-07-04	2008-02-21	Esencia Co., Ltd.	Sterilizer for baby products
TWI430806B (zh)	2006-09-13	2014-03-21	Smithkline Beecham Corp	用於投與長效降血糖藥劑之方法
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
EP2084182B1 (en) *	2006-10-03	2013-08-28	Cadila Healthcare Limited	Antidiabetic compounds
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
RU2432361C2 (ru) *	2007-01-05	2011-10-27	КовЭкс Текнолоджиз Айэлэнд Лимитед	Соединения агонисты рецептора глюкагоноподобного белка-1 (glp-1r)
RU2477286C2 (ru) *	2007-01-05	2013-03-10	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
AU2008216265B2 (en) *	2007-02-15	2014-04-03	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
AR065809A1 (es)	2007-03-22	2009-07-01	Bristol Myers Squibb Co	Formulaciones farmaceuticas que contienen un inhibidor sglt2
PE20090696A1 (es)	2007-04-20	2009-06-20	Bristol Myers Squibb Co	Formas cristalinas de saxagliptina y procesos para preparar las mismas
US8980830B2 (en) *	2007-10-30	2015-03-17	Indiana University Research And Technology Corporation	Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
WO2009058662A2 (en)	2007-10-30	2009-05-07	Indiana University Research And Technology Corporation	Glucagon antagonists
WO2009125424A2 (en) *	2007-12-11	2009-10-15	Cadila Healthcare Limited	Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
AU2009210570B2 (en) *	2008-01-30	2014-11-20	Indiana University Research And Technology Corporation	Ester-based insulin prodrugs
EP2108960A1 (en)	2008-04-07	2009-10-14	Arena Pharmaceuticals, Inc.	Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
EP2300037B1 (en)	2008-06-17	2016-03-30	Indiana University Research and Technology Corporation	Glucagon/glp-1 receptor co-agonists
WO2009155257A1 (en) *	2008-06-17	2009-12-23	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
DK2300035T3 (en) *	2008-06-17	2015-11-16	Univ Indiana Res & Tech Corp	Mixed GIP-based agonists for the treatment of metabolic diseases and obesity
US8748377B2 (en)	2008-12-10	2014-06-10	Glaxosmithkline Llc	Pharmaceutical compositions
CN102325539A (zh)	2008-12-19	2012-01-18	印第安纳大学研究及科技有限公司	基于酰胺的胰高血糖素超家族肽前药
WO2010148089A1 (en)	2009-06-16	2010-12-23	Indiana University Research And Technology Corporation	Gip receptor-active glucagon compounds
PL2451437T3 (pl) *	2009-07-06	2017-05-31	Sanofi-Aventis Deutschland Gmbh	Wodne preparaty insuliny zawierające metioninę
WO2011048614A2 (en)	2009-10-22	2011-04-28	Cadila Healthcare Limited	Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
EP3315124B1 (en)	2009-11-13	2021-01-06	Astrazeneca AB	Bilayer tablet formulations
CN102711738A (zh)	2009-11-13	2012-10-03	百时美施贵宝公司	质量得以减小的二甲双胍制剂
JP5784623B2 (ja)	2009-11-13	2015-09-24	アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａＡｋｔｉｅｂｏｌａｇ	速放性錠剤製剤
KR20120118008A (ko)	2009-12-18	2012-10-25	아이데닉스 파마슈티칼스, 인코포레이티드	5,5-융합 아릴렌 또는 헤테로아릴렌 간염 ｃ 바이러스 억제제
US8703701B2 (en)	2009-12-18	2014-04-22	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
EP2528618A4 (en)	2010-01-27	2015-05-27	Univ Indiana Res & Tech Corp	GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
TWI562775B (en)	2010-03-02	2016-12-21	Lexicon Pharmaceuticals Inc	Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
JP2013525491A (ja)	2010-05-04	2013-06-20	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	心血管障害を治療または予防し心血管保護を提供する方法
CA2797095A1 (en)	2010-05-13	2011-11-17	Indiana University Research And Technology Corporation	Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
WO2011143208A1 (en)	2010-05-13	2011-11-17	Indiana University Research And Technology Corporation	Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
WO2011143788A1 (en)	2010-05-17	2011-11-24	Zhejiang Beta Pharma Inc.	Novel glucagon like peptide analogs, composition, and method of use
RU2580317C2 (ru)	2010-06-24	2016-04-10	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
RU2013103763A (ru)	2010-07-02	2014-08-10	Ангиохем Инк.	Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения
US8507428B2 (en)	2010-12-22	2013-08-13	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting GIP receptor activity
TWI631963B (zh)	2011-01-05	2018-08-11	雷西肯製藥股份有限公司	包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
CN102250315A (zh) *	2011-05-10	2011-11-23	郑州大学	氨基酸衍生环氧树脂
RS56173B1 (sr)	2011-06-22	2017-11-30	Univ Indiana Res & Tech Corp	Koagonisti receptora za glukagon/glp-1 receptora
BR112013032717A2 (pt)	2011-06-22	2017-01-24	Univ Indiana Res & Tech Corp	coagonistas do receptor de glucagon/glp-1
RU2014117678A (ru)	2011-11-17	2015-12-27	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
CA2877358A1 (en)	2012-06-21	2013-12-27	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting gip receptor activity
CN102920658B (zh) *	2012-11-02	2015-01-21	艾韦特(溧阳)医药科技有限公司	与glp-1类似物和聚乙二醇结合的脂质体及其制备方法
PL3489226T3 (pl)	2012-11-20	2021-08-02	Lexicon Pharmaceuticals, Inc.	Inhibitory kotransportera glukozowo-sodowego 1
WO2014158900A1 (en)	2013-03-14	2014-10-02	Indiana University Research And Technology Corporation	Insulin-incretin conjugates
NZ717930A (en) *	2013-09-17	2018-12-21	Vectus Biosystems Ltd	Compositions for the treatment of hypertension and/or fibrosis
ES2822994T3 (es)	2014-09-24	2021-05-05	Univ Indiana Res & Tech Corp	Conjugados de incretina-insulina
HRP20240485T1 (hr)	2017-08-24	2024-07-05	Novo Nordisk A/S	Pripravci glp-1 i njihova upotreba
US10968192B2 (en)	2018-09-26	2021-04-06	Lexicon Pharmaceuticals, Inc.	Crystalline solid forms of N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide and methods of their synthesis
PE20230819A1 (es)	2020-02-18	2023-05-19	Novo Nordisk As	Composiciones y usos de glp-1
CN115697968B (zh) *	2020-05-28	2024-03-29	杭州中美华东制药有限公司	(s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其盐的制备方法
CN114591418A (zh) *	2020-12-04	2022-06-07	南京大学	PPARγ蛋白的第166位苏氨酸磷酸化修饰及其应用
TW202320858A (zh)	2021-07-19	2023-06-01	美商薩諾管理公司	免疫接合物及方法
US11806405B1 (en)	2021-07-19	2023-11-07	Zeno Management, Inc.	Immunoconjugates and methods

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2019419A (en) *	1931-05-11	1935-10-29	Du Pont	Hydrogenation of pyridine bodies
US3674836A (en)	1968-05-21	1972-07-04	Parke Davis & Co	2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4027009A (en)	1973-06-11	1977-05-31	Merck & Co., Inc.	Compositions and methods for depressing blood serum cholesterol
JPS5612114B2 (no)	1974-06-07	1981-03-18
US4231938A (en)	1979-06-15	1980-11-04	Merck & Co., Inc.	Hypocholesteremic fermentation products and process of preparation
MX7065E (es)	1980-06-06	1987-04-10	Sankyo Co	Un procedimiento microbiologico para preparar derivados de ml-236b
US4450171A (en)	1980-08-05	1984-05-22	Merck & Co., Inc.	Antihypercholesterolemic compounds
US4448784A (en)	1982-04-12	1984-05-15	Hoechst-Roussel Pharmaceuticals, Inc.	1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US5354772A (en)	1982-11-22	1994-10-11	Sandoz Pharm. Corp.	Indole analogs of mevalonolactone and derivatives thereof
US4499289A (en)	1982-12-03	1985-02-12	G. D. Searle & Co.	Octahydronapthalenes
CA1327360C (en)	1983-11-14	1994-03-01	William F. Hoffman	Oxo-analogs of mevinolin-like antihypercholesterolemic agents
EP0144726B2 (de) *	1983-11-17	1995-05-24	Akzo Nobel N.V.	Antimikrobielle Mischungen
US4647476A (en) *	1984-03-05	1987-03-03	General Electric Company	Insulating glass body with electrical feedthroughs and method of preparation
US4613610A (en)	1984-06-22	1986-09-23	Sandoz Pharmaceuticals Corp.	Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en)	1984-07-24	1987-08-11	Sandoz Pharmaceuticals Corp.	Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en)	1984-09-24	1987-03-03	Warner-Lambert Company	Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
EP0216785B1 (en)	1984-12-04	1991-01-30	Sandoz Ag	Indene analogs of mevalonolactone and derivatives thereof
US4613810A (en) *	1985-05-10	1986-09-23	The United States Of America As Represented By The Secretary Of The Navy	High output programmable signal current source for low output impedance applications
US4668794A (en)	1985-05-22	1987-05-26	Sandoz Pharm. Corp.	Intermediate imidazole acrolein analogs
HUT48208A (en)	1985-10-25	1989-05-29	Sandoz Ag	Process for producing heterocyclic analogues of mevalolactone derivatives and pharmaceutical compositions comprising such compounds
US5421992A (en) *	1987-02-17	1995-06-06	Chevron U.S.A. Inc.	Hydrocarbon conversion process using zeolite SSZ-25
FR2596393B1 (fr)	1986-04-01	1988-06-03	Sanofi Sa	Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
US5614492A (en)	1986-05-05	1997-03-25	The General Hospital Corporation	Insulinotropic hormone GLP-1 (7-36) and uses thereof
US4681893A (en)	1986-05-30	1987-07-21	Warner-Lambert Company	Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI89493C (fi)	1987-05-22	1993-10-11	Squibb & Sons Inc	Foerfarande foer framstaellning av terapeutiskt aktiva, fosforhaltiga inhibitorer av hmg-coa-reduktas och vid foerfarandet anvaendbar ny mellanprodukt
US4759923A (en)	1987-06-25	1988-07-26	Hercules Incorporated	Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
JP2569746B2 (ja)	1987-08-20	1997-01-08	日産化学工業株式会社	キノリン系メバロノラクトン類
US4871721A (en)	1988-01-11	1989-10-03	E. R. Squibb & Sons, Inc.	Phosphorus-containing squalene synthetase inhibitors
US4924024A (en)	1988-01-11	1990-05-08	E. R. Squibb & Sons, Inc.	Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
NO177005C (no)	1988-01-20	1995-07-05	Bayer Ag	Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
US5506219A (en)	1988-08-29	1996-04-09	E. R. Squibb & Sons, Inc.	Pyridine anchors for HMG-CoA reductase inhibitors
US5753675A (en)	1989-03-03	1998-05-19	Novartis Pharmaceuticals Corporation	Quinoline analogs of mevalonolactone and derivatives thereof
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CA2048910C (en) *	1990-08-10	2003-02-25	Newell F. Bascomb	Antimicrobial peptides active against plant pathogens, their method of use and various screening methods pertaining thereto
US5177080A (en)	1990-12-14	1993-01-05	Bayer Aktiengesellschaft	Substituted pyridyl-dihydroxy-heptenoic acid and its salts
AU648140B2 (en) *	1991-02-01	1994-04-14	Virtual Drug Development, Inc.	Reverse antimicrobial peptides and antimicrobial compositions
JP2648897B2 (ja)	1991-07-01	1997-09-03	塩野義製薬株式会社	ピリミジン誘導体
US5595872A (en)	1992-03-06	1997-01-21	Bristol-Myers Squibb Company	Nucleic acids encoding microsomal trigyceride transfer protein
SK155694A3 (en) *	1992-06-15	1995-05-10	Pfizer	Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters
US5470845A (en)	1992-10-28	1995-11-28	Bristol-Myers Squibb Company	Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia
US5516642A (en) *	1992-11-16	1996-05-14	Bristol-Myers Squibb Company	Polypeptides derived from major histocompatibility complex Class I antigen
WO1994014777A1 (en) *	1992-12-28	1994-07-07	Eisai Co., Ltd.	Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar)
US5594016A (en)	1992-12-28	1997-01-14	Mitsubishi Chemical Corporation	Naphthalene derivatives
ES2133158T3 (es)	1993-01-19	1999-09-01	Warner Lambert Co	Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
US5739135A (en)	1993-09-03	1998-04-14	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
US5776983A (en)	1993-12-21	1998-07-07	Bristol-Myers Squibb Company	Catecholamine surrogates useful as β3 agonists
US5488064A (en)	1994-05-02	1996-01-30	Bristol-Myers Squibb Company	Benzo 1,3 dioxole derivatives
US5385929A (en)	1994-05-04	1995-01-31	Warner-Lambert Company	[(Hydroxyphenylamino) carbonyl] pyrroles
US5612359A (en)	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
US5491134A (en)	1994-09-16	1996-02-13	Bristol-Myers Squibb Company	Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en)	1994-12-02	1996-07-30	Bristol-Myers Squibb Company	Aryloxypropanolamine β 3 adrenergic agonists
US5620997A (en)	1995-05-31	1997-04-15	Warner-Lambert Company	Isothiazolones
WO1997012613A1 (en)	1995-10-05	1997-04-10	Warner-Lambert Company	Method for treating and preventing inflammation and atherosclerosis
AU717743B2 (en)	1995-12-13	2000-03-30	Regents Of The University Of California, The	Nuclear receptor ligands and ligand binding domains
US5770615A (en)	1996-04-04	1998-06-23	Bristol-Myers Squibb Company	Catecholamine surrogates useful as β3 agonists
US5962440A (en)	1996-05-09	1999-10-05	Bristol-Myers Squibb Company	Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method
US5827875A (en)	1996-05-10	1998-10-27	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
US5885983A (en)	1996-05-10	1999-03-23	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
IL128332A0 (en) *	1996-08-30	2000-01-31	Novo Nordisk As	GLP-1 derivatives
US5760246A (en)	1996-12-17	1998-06-02	Biller; Scott A.	Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
TW536540B (en)	1997-01-30	2003-06-11	Bristol Myers Squibb Co	Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9713739D0 (en)	1997-06-27	1997-09-03	Karobio Ab	Thyroid receptor ligands
WO1999003880A1 (en)	1997-07-15	1999-01-28	Novo Nordisk A/S	Nociceptin analogues
US6380357B2 (en) *	1997-12-16	2002-04-30	Eli Lilly And Company	Glucagon-like peptide-1 crystals
AU766219B2 (en)	1998-02-02	2003-10-09	1149336 Ontario Inc.	Method of regulating glucose metabolism, and reagents related thereto
ATE366115T1 (de) *	1998-02-13	2007-07-15	Amylin Pharmaceuticals Inc	Inotropische und diuretische effekte von exendin und glp-1
AU3034299A (en)	1998-03-09	1999-09-27	Fondatech Benelux N.V.	Serine peptidase modulators
FR2777283B1 (fr) *	1998-04-10	2000-11-24	Adir	Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19823831A1 (de)	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de)	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
WO2000001389A1 (en)	1998-07-06	2000-01-13	Bristol-Myers Squibb Co.	Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2000012116A1 (en)	1998-08-28	2000-03-09	Eli Lilly And Company	Method for administering insulinotropic peptides
US6461834B1 (en) *	1998-11-06	2002-10-08	Bionebraska, Inc.	Clostripain catalyzed amidation of peptides
DE69922043T2 (de) *	1998-12-07	2005-11-24	Société de Conseils de Recherches et d'Applications Scientifiques S.A.S.	Glp-1 analoge
JP2002538081A (ja) *	1998-12-07	2002-11-12	ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス	Ｇｌｐ−１の類似体
DK1143989T3 (da) *	1999-01-14	2007-04-16	Amylin Pharmaceuticals Inc	Exendiner til glucagonundertrykkelse
NZ512663A (en) *	1999-01-14	2004-05-28	Amylin Pharmaceuticals Inc	Novel exendin agonist formulations and methods of administration thereof
JP2002544127A (ja) *	1999-04-30	2002-12-24	アミリン・ファーマシューティカルズ，インコーポレイテッド	修飾されたエキセンジンおよびエキセンジン・アゴニスト
CA2363712C (en) *	1999-05-17	2011-05-10	Conjuchem Inc.	Long lasting insulinotropic peptides
US6344180B1 (en) *	1999-06-15	2002-02-05	Bionebraska, Inc.	GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
JP3357356B2 (ja)	1999-12-13	2002-12-16	中外製薬株式会社	ヒドロキシカルボニル−ハロゲノアルキル側鎖を有する化合物
EP1208092B1 (en)	2000-04-07	2006-06-21	Samsung Electronics Co., Ltd.	Sulfonamide derivative as a matrix metalloproteinase inhibitor
ATE424413T1 (de) *	2000-06-16	2009-03-15	Lilly Co Eli	Analoge des glucagon-ähnlichen peptids-1
US6579889B2 (en)	2000-06-22	2003-06-17	Merck & Co., Inc.	Substituted isonipecotyl derivatives as inhibitors of cell adhesion
BR0116024A (pt) *	2000-12-07	2005-12-13	Lilly Co Eli	Proteìna de fusão heteróloga e uso da mesma
US7259233B2 (en) *	2000-12-13	2007-08-21	Eli Lilly And Company	Chronic treatment regimen using glucagon-like insulinotropic peptides
US7385025B2 (en) *	2000-12-19	2008-06-10	Palatin Technologies, Inc.	Metallopeptide compounds
US7144863B2 (en) *	2001-06-01	2006-12-05	Eli Lilly And Company	GLP-1 formulations with protracted time action
CA2463908A1 (en)	2001-10-18	2003-04-24	Bristol-Myers Squibb Company	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7238671B2 (en)	2001-10-18	2007-07-03	Bristol-Myers Squibb Company	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
TW200611704A (en) *	2004-07-02	2006-04-16	Bristol Myers Squibb Co	Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US7145040B2 (en) *	2004-07-02	2006-12-05	Bristol-Myers Squibb Co.	Process for the preparation of amino acids useful in the preparation of peptide receptor modulators

2002
- 2002-10-18 CA CA002463908A patent/CA2463908A1/en not_active Abandoned
- 2002-10-18 GE GE5582A patent/GEP20063908B/en unknown
- 2002-10-18 CN CNA028205588A patent/CN1630709A/zh active Pending
- 2002-10-18 AU AU2002348469A patent/AU2002348469B2/en not_active Ceased
- 2002-10-18 KR KR10-2004-7005731A patent/KR20040054729A/ko not_active Ceased
- 2002-10-18 MX MXPA04003553A patent/MXPA04003553A/es active IP Right Grant
- 2002-10-18 WO PCT/US2002/033386 patent/WO2003033671A2/en not_active Ceased
- 2002-10-18 US US10/273,975 patent/US7238670B2/en not_active Expired - Lifetime
- 2002-10-18 EP EP02782185A patent/EP1572892A4/en not_active Withdrawn
- 2002-10-18 RU RU2004114836/04A patent/RU2353625C2/ru not_active IP Right Cessation
- 2002-10-18 YU YU31004A patent/YU31004A/sh unknown
- 2002-10-18 JP JP2003536401A patent/JP2005514337A/ja active Pending
- 2002-10-18 HU HU0700151A patent/HUP0700151A2/hu unknown
- 2002-10-18 NZ NZ531788A patent/NZ531788A/en unknown
- 2002-10-18 IL IL16091702A patent/IL160917A0/xx unknown
- 2002-10-18 HR HR20040343A patent/HRP20040343A2/hr not_active Application Discontinuation
- 2002-10-18 BR BRPI0213377-6A patent/BR0213377A/pt not_active IP Right Cessation
- 2002-10-18 PL PL377687A patent/PL377687A1/pl not_active Application Discontinuation
2004
- 2004-03-16 IS IS7185A patent/IS7185A/is unknown
- 2004-03-23 NO NO20041203A patent/NO20041203L/no not_active Application Discontinuation
- 2004-04-15 ZA ZA200402846A patent/ZA200402846B/en unknown
2007
- 2007-04-25 US US11/740,031 patent/US20070287670A1/en not_active Abandoned
2010
- 2010-04-30 US US12/771,096 patent/US20100210552A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20070287670A1 (en)	2007-12-13
JP2005514337A (ja)	2005-05-19
CN1630709A (zh)	2005-06-22
WO2003033671A3 (en)	2005-12-29
HRP20040343A2 (en)	2005-08-31
EP1572892A4 (en)	2007-08-22
ZA200402846B (en)	2005-08-16
NZ531788A (en)	2008-01-31
RU2004114836A (ru)	2005-04-10
CA2463908A1 (en)	2003-04-24
YU31004A (sh)	2006-08-17
AU2002348469B2 (en)	2008-03-13
MXPA04003553A (es)	2004-07-22
US20100210552A1 (en)	2010-08-19
IL160917A0 (en)	2004-08-31
HUP0700151A2 (en)	2007-05-29
RU2353625C2 (ru)	2009-04-27
KR20040054729A (ko)	2004-06-25
WO2003033671A2 (en)	2003-04-24
PL377687A1 (pl)	2006-02-06
BR0213377A (pt)	2006-05-23
IS7185A (is)	2004-03-16
US20030195157A1 (en)	2003-10-16
GEP20063908B (en)	2006-08-25
EP1572892A2 (en)	2005-09-14
US7238670B2 (en)	2007-07-03

Legal Events

Date	Code	Title	Description
2010-05-31	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20041203L (no)	2004-06-10	Human glukagonlignende peptid-1 etterligner og deres anvendelse i behandling av diabetes og relaterte tilstander.
EE200300485A (et)	2004-02-16	Tiohüdantoinid ja nende kasutamine diabeedi raviks
DE60222671D1 (de)	2007-11-08	Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
NO20034169L (no)	2003-11-18	MCH-antagonister og deres anvendelse ved behandling av fedme
NO20023566D0 (no)	2002-07-26	Propionsyrederivater og deres anvendelse ved behandling av sukkkersyke og fedme
NO20043370L (no)	2004-09-28	N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer
DK1392292T3 (da)	2006-05-29	Pyranoindazoler og deres anvendelse til behandling af glaukom
DK1404809T3 (da)	2014-03-17	Forbedrede hudsubstitutter og anvendelser deraf
IS5756A (is)	2000-12-08	Notkun hreinljósvirks (+) -norkisapríðs við meðhöndlun á öndunarstöðvun, lotugræðgi og öðrum meinum
IS8392A (is)	2006-03-31	Heterósýklískir hindrar MEK og notkun þeirra
NO20022680L (no)	2002-08-12	Farmasoytiske kombinasjoner og deres anvendelse ved behandling av gastrointestinale forstyrrelser
NO20034437L (no)	2003-12-02	Gangliosid-assosierte rekombinante antistoffer og anvendelse derav ved diagnostikk og behandling av tumorer
IS2482B (is)	2008-12-15	Arómatísk súlfón og læknisfræðileg notkun þeirra
NO20033123D0 (no)	2003-07-08	Terapeutisk hinnedannende sammensetning og behandlingsplan derav
IS6966A (is)	2003-09-24	Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
IS6967A (is)	2003-09-24	Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
NO20024924D0 (no)	2002-10-11	Anvendelse av bradykardiale substanser ved behandling av myokardiale sykdommer i forbindelse med hypertrofi og nyemedikamentkombinasjoner
IS7203A (is)	2004-03-31	4[píperidín-4-ýliden-(3-karbamólýlfenýl)metýl]bensamíðafleiður og notkun þeirra til að meðhöndla verki, mænuskaða eða maga- og garnasjúkdóma
NO20052698D0 (no)	2005-06-06	4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gasatrintestinale lidelser.
IS7026A (is)	2003-11-11	4-(fenýl-píperidín-4-ýlíden-metýl)-bensamíðafleiður og notkun þeirra til meðhöndlunar á sársauka, kvíða eða truflunum í maga og þörmum
DE60204755D1 (de)	2005-07-28	"3,7-diazabicyclo(3.3.0)octane und deren verwendung bei der behandlung von herzrhythmusstörungen"
NO20052699D0 (no)	2005-06-06	4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
EE200300527A (et)	2004-02-16	4-(fenüülpiperidiin-4-ülideenmetüül)bensamiidi derivaadid ja nende kasutamine valu, ärevuse või seedetrakti häirete raviks
IS5755A (is)	2000-12-08	Notkun hreinljósvirks (-) norkisapríðs við meðhöndlun á öndunarstöðvun, lotugræðgi og öðrum meinum
NO20043029L (no)	2004-10-11	Karboksamidinderivater og deres anvendelse ved behandling av vaskulaere sykdommer